These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. HMG-CoA reductase inhibitors activate caspase-1 in human monocytes depending on ATP release and P2X7 activation. Liao YH; Lin YC; Tsao ST; Lin YC; Yang AJ; Huang CT; Huang KC; Lin WW J Leukoc Biol; 2013 Feb; 93(2):289-99. PubMed ID: 23159926 [TBL] [Abstract][Full Text] [Related]
9. Leptin enhances the secretion of interleukin (IL)-18, but not IL-1β, from human monocytes via activation of caspase-1. Jitprasertwong P; Jaedicke KM; Nile CJ; Preshaw PM; Taylor JJ Cytokine; 2014 Feb; 65(2):222-30. PubMed ID: 24275551 [TBL] [Abstract][Full Text] [Related]
10. Modulation of COX-2 expression by statins in human monocytic cells. Habib A; Shamseddeen I; Nasrallah MS; Antoun TA; Nemer G; Bertoglio J; Badreddine R; Badr KF FASEB J; 2007 Jun; 21(8):1665-74. PubMed ID: 17317725 [TBL] [Abstract][Full Text] [Related]
11. Defect in mevalonate pathway induces pyroptosis in Raw 264.7 murine monocytes. Marcuzzi A; Piscianz E; Girardelli M; Crovella S; Pontillo A Apoptosis; 2011 Sep; 16(9):882-8. PubMed ID: 21667041 [TBL] [Abstract][Full Text] [Related]
12. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin. Hu WL; Qiao SB; Li JJ Cytokine; 2007 Dec; 40(3):201-6. PubMed ID: 18023360 [TBL] [Abstract][Full Text] [Related]
13. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Thurnher M; Nussbaumer O; Gruenbacher G Clin Cancer Res; 2012 Jul; 18(13):3524-31. PubMed ID: 22529099 [TBL] [Abstract][Full Text] [Related]
14. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Waehre T; Yndestad A; Smith C; Haug T; Tunheim SH; Gullestad L; Frøland SS; Semb AG; Aukrust P; Damås JK Circulation; 2004 Apr; 109(16):1966-72. PubMed ID: 15051633 [TBL] [Abstract][Full Text] [Related]
15. Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Liang YJ; Shyu KG; Wang BW; Lai LP Cardiology; 2008; 110(3):182-90. PubMed ID: 18057884 [TBL] [Abstract][Full Text] [Related]
16. Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-activated protein kinase pathway. Song JX; Ren JY; Chen H J Cardiovasc Pharmacol; 2011 Feb; 57(2):213-22. PubMed ID: 21052011 [TBL] [Abstract][Full Text] [Related]
17. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Frenkel J; Rijkers GT; Mandey SH; Buurman SW; Houten SM; Wanders RJ; Waterham HR; Kuis W Arthritis Rheum; 2002 Oct; 46(10):2794-803. PubMed ID: 12384940 [TBL] [Abstract][Full Text] [Related]
18. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation. Lee MH; Cho YS; Han YM Stem Cells; 2007 Jul; 25(7):1654-63. PubMed ID: 17464088 [TBL] [Abstract][Full Text] [Related]
19. HMG-CoA reductase inhibitor simvastatin inhibits proinflammatory cytokine production from murine mast cells. Kagami S; Kanari H; Suto A; Fujiwara M; Ikeda K; Hirose K; Watanabe N; Iwamoto I; Nakajima H Int Arch Allergy Immunol; 2008; 146 Suppl 1():61-6. PubMed ID: 18504409 [TBL] [Abstract][Full Text] [Related]